Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809
K Ohmachi, K Tobinai, Y Kobayashi, K Itoh, M Nakata, T Shibata, Y Morishima, M Ogura, T Suzuki, R Ueda, K Aikawa, S Nakamura, H Fukuda, M Shimoyama, T Hotta, members of the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), K Ohmachi, K Tobinai, Y Kobayashi, K Itoh, M Nakata, T Shibata, Y Morishima, M Ogura, T Suzuki, R Ueda, K Aikawa, S Nakamura, H Fukuda, M Shimoyama, T Hotta, members of the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG)
Abstract
Background: CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma (NHL), and dose intensification is a potential strategy for improving therapeutic results. We conducted a phase III trial to determine whether dose-dense strategy involving interval shortening of CHOP (CHOP-14) is superior to CHOP-21.
Patients and methods: A total of 323 previously untreated patients (aged 15-69 years) with stages II-IV aggressive NHL were randomized. The primary end point was progression-free survival (PFS).
Results: Treatment compliance was comparable in both study arms. At 7-year follow-up, no substantial differences were observed in PFS and overall survival (OS) between CHOP-21 (n = 161) and CHOP-14 (n = 162) arms. Median PFS was 2.8 and 2.6 years with CHOP-21 and CHOP-14, respectively (one-sided log-rank P = 0.79). Eight-year OS and PFS rates were 56% and 42% [95% confidence interval (CI) 47% to 64% and 34% to 49%], respectively, with CHOP-21 and 55% and 38% (95% CI 47% to 63% and 31% to 46%), respectively, with CHOP-14. Subgroup analyses showed no remarkable differences in PFS or OS for patients stratified as per the International Prognostic Index or by age.
Conclusion: Dose-intensification strategy involving interval shortening of CHOP did not prolong PFS in advanced, aggressive NHL.
Trial registration: ClinicalTrials.gov NCT00133302.
Source: PubMed